Genialis, Inc.

Genialis, Inc. is a US-based precision oncology company specializing in advanced products that enhance therapeutic intelligence and biomarker discovery for cancer treatment. Founded in 2015 in Boston, US, Genialis, Inc. operates as a precision oncology firm offering unique solutions for cancer treatment.

The company has been involved in 2 deals, with its latest funding round being a Series A in January 2023, raising USD 11. 42 mn. The founders include Lino Gomez and Rafael Rosengarten, who also serve as CEO. The firm has not undergone any notable pivots or changes in its business strategy since its inception.

Genialis, Inc. provides a suite of advanced products aimed at enhancing therapeutic intelligence and biomarker discovery. Key products include Genialis™ krasID, Genialis™ Supermodel, and Genialis ResponderID™, utilizing proprietary AI methodologies and a diverse global dataset to offer actionable insights for oncology. Their solutions support a wide client base, including pharmaceutical companies and research institutions, primarily across North America, Europe, and parts of Asia.

Genialis generates revenue through a subscription-based model, offering its proprietary platforms via structured agreements. Clients, which include both large pharmaceutical companies and smaller research organizations, commit to annual or multi-year contracts to access products like Genialis™ krasID and Genialis™ Supermodel. Specific pricing details are not publicly disclosed, but the model facilitates a variety of usage scenarios across its offerings. In January 2023, Genialis, Inc.

raised USD 11. 42 mn in Series A funding, co-led by Debiopharm Innovation Fund and Taiwania Capital. This funding will be utilized to develop clinical biomarkers aimed at predicting patient responses. The company plans to expand its offerings and explore new markets, although specific geographic targets have not been disclosed.